Recent 8-K filings for SRTA
Highest-materiality recent filing
Strata Critical Medical closes Passenger sale to Joby for ~$76M in stock; shifts to medical transport
- Completed sale of Passenger business to Joby Aero on Aug 29; received ~$76M in 5.3M Joby shares, plus up to $35M earnout and $10M holdbacks.
- Name changed to Strata Critical Medical; Nasdaq tickers become SRTA (common) and SRTAW (warrants).
-
Strata Critical Medical Q1 revenue up 87% to $67.4M; net income $2.4M vs prior loss
Revenue $67.4M (up 87.4% YoY); net income from cont. ops $2.4M vs loss of $1.6M YoY.
-
Strata Critical Medical Q4 revenue up 83.5% YoY to $66.8M; raises FY2026 guidance
Q4 2025 revenue $66.8M (+83.5% YoY); logistics revenue up 35.3% to $49.2M.
-
Strata Critical Medical secures $30M ABL credit facility from JPMorgan for acquisitions
Entered Credit Agreement for up to $30M revolving ABL facility, expandable to $50M subject to conditions.
-
Strata Critical Medical amends 8-K to include Keystone financials; acquisition closed
Acquisition of Keystone Perfusion Services closed Sep 16, 2025; all equity interests acquired.
-
Strata Critical Medical Q3 revenue up 36.7% to $49.3M; net loss widens to $9.7M
Revenue $49.3M, up 36.7% YoY; organic growth 29.0% excluding Keystone acquisition.
-
Strata completes $124M acquisition of Keystone Perfusion, updates 2025 guidance
Total upfront consideration of $124M (88% cash, 12% stock) at ~9x Keystone's estimated 2025 Adjusted EBITDA of ~$13M.
-
Strata Critical Medical appoints Co-CEOs Tomkiel and Heyburn, approves $550K salary and PSUs
Melissa Tomkiel and William Heyburn became Co-CEOs effective Aug 1, 2025, retaining General Counsel and CFO roles respectively.
-
Completed sale of Passenger business to Joby Aero on Aug 29; received ~$76M in 5.3M Joby shares, plus up to $35M earnout and $10M holdbacks.
-
Blade Air Mobility Q2 net loss narrows to $3.7M; sells Passenger division to Joby for up to $125M
Q2 net loss improved $7.6M YoY to $(3.7)M; Adjusted EBITDA $3.2M vs $0.96M YoY.
-
Blade sells passenger division to Joby for up to $125M; to rebrand as Strata
Up to $125M consideration (cash or Joby stock): $90M at close plus up to $35M earnout tied to performance and retention.
-
Blade Air Mobility Q4 revenue up 14.5% to $54.4M; Net loss narrows 71% YoY
Q4 revenue $54.4M (+14.5% YoY); net loss improved 71% to $(9.8)M from $(33.9)M.
-
Blade Air Mobility Q2 net loss narrows to $11.3M; first public Q2 with positive Adj. EBITDA $1.0M
Net loss of $11.3M improved $0.9M YoY; revenue $67.9M up 11.4% YoY.
-
Blade Q1 net loss narrows to $4.2M; Medical revenue record $36M, up 34.6% YoY
Total Q1 revenue of $51.5M, up 13.8% YoY; Medical segment revenue hit a record $36.0M.
-
Blade Air Mobility announces up to $20M share repurchase program; expects FY2024 adj. EBITDA profit
Board authorized repurchase of up to $20M of Class A common stock; program effective through March 31, 2025.
-
Blade Q4 revenue up 24.5% to $47.5M; guides for 2024 Adj. EBITDA profitability
Q4 revenue $47.5M (+24.5% YoY); full year revenue $225.2M (+54.1%).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event earnings